Patient–doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center
Authors Hefner J, Berberich S, Lanvers E, Sanning M, Steimer AK, Kunzmann V
Received 27 March 2018
Accepted for publication 10 July 2018
Published 21 September 2018 Volume 2018:12 Pages 1875—1887
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Jochen Hefner,1 Sara Berberich,2 Elena Lanvers,3 Maria Sanning,4 Ann-Kathrin Steimer,5 Volker Kunzmann6
1Section of Psychosomatic Medicine, Department of Internal Medicine II, University of Wuerzburg, Bavaria, Germany; 2Medical Student, Faculty of Medicine, University of Wuerzburg, Bavaria, Germany; 3Intensive Care Unit, Children’s Hospital of the City of Cologne, North Rhine-Westphalia, Germany; 4Department of Internal Medicine II, St Johannes Hospital Dortmund, North Rhine-Westphalia, Germany; 5Catholic Children’s Hospital Wilhelmsstift, Hamburg, Germany; 6Section of Clinical Oncology, Department of Internal Medicine II, University of Wuerzburg, Bavaria, Germany
Purpose: The prescribing of oral chemotherapy agents has introduced the new challenge of ensuring patients’ adherence to therapy. Aspects of a close patient–doctor relationship are reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine are scarce.
Patients and methods: Sixty-four outpatients with a diagnosis of cancer and prescribed capecitabine were recruited from a German Comprehensive Cancer Center. We used the Patient–Doctor Relationship Questionnaire (PDRQ-9), the Medical Adherence Rating Scale (MARS), the Beliefs about Medicines Questionnaire (BMQ), and the Satisfaction with Information about Medicines Scale (SIMS) to assess patients’ perceptions and behavior. Medical data were extracted from the charts.
Results: Non-adherence was reported by 20% of the 64 participants. The perceived quality of the patient–doctor relationship was high in general, but it did not emerge as a predictor of adherence in our survey (odds ratio [OR]=0.915, P=0.162, 95% CI=0.808–1.036). However, beliefs about medicine (OR=1.268, P<0.002; 95% CI=1.090–1.475) as well as satisfaction with information about medicine (OR=1.252, P<0.040, 95% CI=1.010–1.551) were predictors of adherence and the quality of the patient–doctor relationship was correlated with both variables (r=0.373, P=0.002 for SIMS sum score; r=0.263, P=0.036 for BMQ necessity/concern difference). Overall, adherence to capecitabine was high with a conviction that the therapy is necessary. However, concerns were expressed regarding the long-term effect of capecitabine use. Patients have unmet information needs regarding interactions of capecitabine with other medicines and the impairment of their intimate life.
Conclusions: In order to ensure adherence to capecitabine, our results seem to encourage the default use of modern and perhaps more impersonal means of information brokerage (eg, email, internet). However, the contents of some of patients’ informational needs as well as the associations of patients’ beliefs and satisfaction about the information received suggest a benefit from a trustful patient–doctor relationship.
Keywords: oral anticancer drugs, capecitabine, adherence, patient–doctor relationship, beliefs in medication, satisfaction with information about medicines
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]